Use of irinotecan for treatmentof small cell carcinoma of the prostate

Prostate

Volumn 71, Issue 7, 2011, Pages 675-681

  Tung, Wei Lin ^a,b,c   Wang, Yuwei ^a,b   Gout, Peter W ^b   Liu, Dean Mo ^c   Gleave, Martin ^a   Wang, Yuzhuo ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

Autophagy; Irinotecan; Prostate; Small cell carcinoma; Subrenal capsule xenografts

Indexed keywords

CASPASE 3; CISPLATIN; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SMALL CELL CARCINOMA; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; CELL SURVIVAL; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; MALE; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; AUTOPHAGY; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG THERAPY, COMBINATION; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; PROSTATIC NEOPLASMS; SUBRENAL CAPSULE ASSAY;

EID: 79953688703     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21283     Document Type: Article

References (32)

1. Lopez-Barcons LA. Small-cell neuroendocrine carcinoma of the prostate: Are heterotransplants a better experimental model? Asian J Androl 2010;12(3):308-314.
2. Wenk RE, Bhagavan BS, Levy R, Miller D, Weisburger W. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer 1977;40(2):773-778. (Pubitemid 8177897)
3. Stein ME, Bernstein Z, Abacioglu U, Sengoz M, Miller RC, Meirovitz A, Zouhair A, Freixa SV, Poortmans PH, Ash R, Kuten A. Small cell (neuroendocrine) carcinoma of the prostate: Etiology, diagnosis, prognosis, and therapeutic implications - A retrospective study of 30 patients from the rare cancer network. Am J Med Sci 2008;336(6):478-488.
4. Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001;12 (Suppl 2):S145-S152. (Pubitemid 33069705)
5. Moore SR, Reinberg Y, Zhang G. Small cell carcinoma of prostate: Effectiveness of hormonal versus chemotherapy. Urology 1992;39(5):411-416.
6. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: A clinical, pathological and immunohistological study of 27 patients. J Urol 1992;147(3 Pt 2):804-807.
7. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987;59(10):1803-1809.
8. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004;64(24):9209-9216. (Pubitemid 39665537)
9. Aoki H, Ishidoya S, Ito A, Endoh M, Shimazui T, Arai Y. Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate. Int J Urol 2006;13(9):1254-1258. (Pubitemid 44410923)
10. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: Small cell carcinoma of the prostate. Semin Oncol 2007;34(1):22-29. (Pubitemid 46161758)
11. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20(14):3072-3080. (Pubitemid 34791096)
12. Blunt DM, Sansom HE, King DM. Imaging of small cell carcinoma of the male urogenital tract. Clin Radiol 1996;51(10):724-727.
13. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2007;2(2):247-250. (Pubitemid 47040037)
14. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn PA, Jr., Carney D, Minna JD, Mulshine JL. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 1996;24:32-91.
15. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432(7015):332-337. (Pubitemid 39551661)
16. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9(11):4227-4239. (Pubitemid 37204044)
17. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, Hayward SW. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005;64(2):149-159. (Pubitemid 40791764)
18. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005;96(1):48-55. (Pubitemid 39612416)
19. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: Potential models for studying tumor progression-related changes. Clin Cancer Res 2006;12(13):4043-4054. (Pubitemid 44078092)
20. Griffin TW, Bogden AE, Reich SD, Antonelli D, Hunter RE, Ward A, Yu DT, Greene HL, Costanza ME. Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. Cancer 1983;52(12):2185-2192. (Pubitemid 14205932)
21. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996;52(7):1103-1111. (Pubitemid 26338269)
22. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346(2):85-91. (Pubitemid 34438898)
23. Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, Zhan Q. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010;5(6):867-873.
24. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 2005;85(11):1392-1404. (Pubitemid 41509387)
25. Nagano T, Yasunaga M, Goto K, Kenmotsu H, Koga Y, Kuroda J, Nishimura Y, Sugino T, Nishiwaki Y, Matsumura Y. Antitumor activity of NK012combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment. Clin Cancer Res 2009;15(13):4348-4355.
26. Yamada T, Ohtsubo K, Mouri H, Yamashita K, Yasumoto K, Izumi K, Zen Y, Watanabe H, Yano S. Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. Int J Clin Oncol 2009;14(5):468-472.
27. Chintala S, Toth K, Yin MB, Bhattacharya A, Smith SB, Ola MS, Cao S, Durrani FA, Zinia TR, Dean R, Slocum HK, Rustum YM. Downregulation of cystine transporter x(c) by irinotecan in human head and neck cancer FaDu xenografts. Chemotherapy 2010;56(3):223-233.
28. Lo M, Wang YZ, Gout PW. The x(c)-cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases. J Cell Physiol 2008;215(3):593-602. (Pubitemid 351632680)
29. Lo M, Ling V, Low C, Wang YZ, Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol 2010;17(3):9-16.
30. Oizumi S, Isobe H, Ogura S, Ishida T, Yamazaki K, NishimuraM, Kawakami Y, Dosaka-Akita H. Topoisomerase inhibitorinduced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells. Anticancer Res 2002;22(6C):4029-4037. (Pubitemid 36134429)
31. Chen N, Debnath J. Autophagy and tumorigenesis. FEBS Lett 2010;584(7):1427-1435.
32. Corcelle EA, Puustinen P, Jaattela M. Apoptosis and autophagy: Targeting autophagy signalling in cancer cells - 'Trick or treats'? FEBS J 2009;276(21):6084-6096.